ATLASMaze Therapeutics (MAZE) earnings date: Nov 5, 2026
Maze Therapeutics (MAZE) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, after the close. Analysts expect EPS of -$0.78.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on MAZE
| Last price | $29.99 (-4.7%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.5% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Maze Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Maze Therapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Maze Therapeutics. You can switch it off at any time.
Alert me before MAZE reportsFree to start. Creating an account takes under a minute.
Notify me when Maze Therapeutics reports
Track MAZE free Add Maze Therapeutics to a free ATLAS watchlist and see its next report date in one place.
MAZE earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.78 |
| Last report | Aug 11, 2026 · Miss |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | +7.4% |
| Average move around a report | ±8.6% (last 5) |
| Sector | Healthcare · Biotechnology |
Maze Therapeutics earnings history: last 5 reports
Maze Therapeutics last reported on Aug 11, 2026: EPS of -$0.76 against an estimate of -$0.70 (-8.6% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 11, 2026 | -$0.70 | -$0.76 | -8.6% | Miss | +0.9% |
| Mar 25, 2026 | -$0.69 | -$0.65 | +5.8% | Beat | -35.3% |
| Nov 6, 2025 | -$0.69 | -$0.66 | +4.3% | Beat | -5.5% |
| Oct 15, 2025 | $1.34 | $1.37 | +2.2% | Beat | -0.2% |
| Aug 12, 2025 | -$1.15 | -$0.77 | +33.0% | Beat | +1.0% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for MAZE
See the fair value, the probability range and the earnings history of Maze Therapeutics on its ATLAS page.
Maze Therapeutics (MAZE) stock analysisPlans from €3.99 a month.
Maze Therapeutics earnings: frequently asked questions
When does Maze Therapeutics (MAZE) report earnings?
Maze Therapeutics is scheduled to report on Thursday, November 5, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for MAZE?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.78 per share (USD). Estimates can change before the report.
How often does MAZE beat earnings estimates?
Of its last 5 reports with a recorded result, Maze Therapeutics beat the EPS estimate 4 times; the average surprise was +7.4%. Past results do not predict the next one.
How much does MAZE move around earnings?
Over its last 5 reports the stock moved an average of 8.6% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did Maze Therapeutics beat earnings estimates last quarter?
Maze Therapeutics last reported on Aug 11, 2026: EPS of -$0.76 against an estimate of -$0.70 (-8.6% surprise), a miss.
How much does MAZE usually move in a day?
On a normal trading day the ATLAS model puts MAZE’s one-day range at about ±3.5%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer